 |
[ Outlaw Genealogy | Bruce
History | Lost Chords ] [ Resources | Ufo | [ Projects | News | FAQ | Suggestions | Search | HotLinks ] |
|
[ Outlaw Genealogy | Bruce
History | Lost Chords ] [ Resources | Ufo | [ Projects | News | FAQ | Suggestions | Search | HotLinks ] |
Scientist says Hepatitis C is 5 time
more deadly then Hep B. And what is Hepatitis D?
Ask
why - Merck pushed Hepatitis B vaccine on newborns? - Vaccine Schedule 1983 vs.
2008
See the whole thread: Aflatoxin
- Hepatitis B - Liver Cancer - Genetic Warfare - Eugenics
http://www.taipeitimes.com/News/taiwan/archives/2009/06/18/2003446487
Hepatitis C raises risk of liver cancer, expert warns
CAUTION: Michael Lai of the Academia Sinica said that risks are high given the
lack of a vaccine for hepatitis C, with medication only effective in 50 percent
of cases
By Meggie Lu STAFF REPORTER
Thursday, Jun 18, 2009, Page 2
Contrary to previous findings, people with hepatitis C are five times as
likely to develop liver cancer as those with hepatitis B, a leading
researcher said yesterday.
Speaking at the 12th Society of Chinese Bioscientists in America (SCBA)
International Symposium, Michael Lai (賴明詔), vice president
of Academia Sinica, said that combined with heavy drinking, the risk level rises
to 10 times.
Lai made the statement during the presentation of his latest paper, "A
journey through RNA viruses: From coronavirus to hepatitis C virus replication
and pathogenesis."
Nicknamed “the father of coronavirus,” Lai yesterday also received the SCBA
Lifetime Achievement Award, the highest SCBA honor.
Hepatitis is a common illness of the liver, which affects millions of people in
Asia. While the prevalence of hepatitis C in Taiwan is 2 percent, it is higher
for hepatitis B.
“There are hepatitis A, B, C, D and E; While hepatitis A and E are acute,
B, C and D are chronic liver diseases,” said Lai, who is also the
president of National Cheng Kung University.
In the past, up to 90 percent of the nation's liver cancer cases were caused by
hepatitis B, but this has been reversed since the development of the hepatitis B
vaccine, he said.
“In southern Taiwan, more than half of liver cancer cases are induced by
hepatitis C,” Lai said.
“Because the disease does not yet have a vaccine and medication is also
only effective in 50 percent of cases, it is very important that we work on
developing a hepatitis C vaccine,” he said.
Lai added that the probability of hepatitis C patients getting liver cancer
was much higher than those with hepatitis B.
“While the amount of time that the hepatitis C virus is found in the human
body is usually shorter — because whereas most hepatitis B patients contract
the virus in early childhood, many hepatitis C patients get the disease later
in life — those with hepatitis C are five times as likely as their
counterparts to develop liver cancer,” he said.
The risks of people with hepatitis C contracting liver cancer could rise
another two-fold — or 10 times more than the risk level for people with
hepatitis B — if they are heavy drinkers or consume a large amount of
high-fat foods, Lai said.
Hepatitis C sufferers should therefore abstain from alcohol and engage in
routine liver function checks every four months, he said.
“Many people in the south go to local pharmacies to receive 'nutrient
injections,' an effort to give their livers supplements,” Lai said.
“However, this kind of behavior may only make their conditions worse,” he
said.
Rose Medical Center tech may have infected patients
http://www.denverpost.com/breakingnews/ci_12745889?source=rss
By Joey Bunch The Denver Post Updated: 07/02/2009 10:00:48 PM MDT
A Rose Medical Center operating room technician, who was fired after failing a
drug test for a powerful pain medication, potentially infected thousands of
patients with hepatitis C, hospital officials
and federal prosecutors said tonight.
Hospital officials said they knew the technician had the virus when she was
hired. [LIHOP? MIHOP?] She began work on
Oct. 21, 2008. She was fired on April 13.
Rose is offering free testing to all people who had surgery in the main
hospital or the Wolf Building between those dates. Letters will be sent to more
than 4,700 former patients. Maternity and emergency room patients are not
affected.
Hospital officials stressed at a Thursday night news conference that the
employee is not confirmed to be the source of the infection and the Colorado
Health Department is continuing its investigation.
Hospital officials would not identify the technician, but court papers
obtained by the Gazette newspaper in Colorado Springs identified her as Kristen
Diane Parker, 26, of Colorado Springs. She is in federal custody.
Quoting paperwork on the charges obtained from a Department of Justice official,
the Gazette said charges against Parker were filed by the U.S. Attorney's office
in Denver on Thursday.
A spokesman for the U.S. Attorney's office did not return telephone calls
Thursday night.
In a videotaped interview with police on Monday, according to the Gazette,
Parker told a detective she used heroin from July to September last year.
She allegedly told the investigator she thought she caught the virus from
injecting herself with dirty needles.
Rose Hospital officials said the state health department had found nine
former Rose patients who tested positive for hepatitis C.
Parker also might have exposed 1,000 patients at Audubon Ambulatory Surgery
Center in Colorado Springs, where she worked after being fired from Rose,
according to the charges against her.
The complaint states Parker admitted exchanging dirty syringes she had
injected herself with and then filled with saline for syringes filled with more
fentanyl.
Fentanyl is a powerful narcotic pain medication given to surgery patients.
Parker allegedly injected the narcotic at home or in the hospital bathrooms,
according to the Gazette.
Jeff Dorsey, the president and chief executive of HealthOne, which operates Rose
and other hospitals, said he was angered by the surgery technician's breach of
trust.
"Someone in this particular case violated the trust everyone has, and that
we value," he said at an evening press conference at the hospital.
Hepatitis C is a contagious liver disease. The Centers for Disease Control and
Prevention estimates more than 8,000 people a year die from hepatitis C-related
liver disease.
Hepatitis C can be treated and cured. Most people have no symptoms.
Dorsey said the technician's behavior led to the drug test that caused her to be
fired immediately. The firing took place before the state health department
contacted the hospital about the possible infections.
Former patients should receive their letter on Tuesday or Wednesday at the
latest, Dorsey said. The hospital also has created a phone line for those
concerned, 303-329-7500. The line will be staffed from 7 a.m. to 7 p.m.
beginning Monday. Dorsey asked that patients wait on a letter before calling.
According the Gazette, Parker told a Denver police investigator in the
videotaped interview, "I know I (expletive) up. I can't take back what I
did, but I will have to live with it for the rest of my life, and so does
everybody else."
She told the investigator she expected to spend the rest of her life in prison.
On her MySpace page, Parker said she is the mother of a young son. She states
that she has "a crazy fascination with needles."
Among the artwork on the page is the figure of a man driven full of nails
beneath the word and definition of, "Guilt ... the fact of having done a
wrong, especially an act punishable by law."
On June 1, a former surgical nurse at Boulder Community Hospital in Boulder
pleaded guilty in federal court to stealing large amounts of a fentanyl for his
own use, while refilling the vials with water. [looks
like a common trend to increase exposure to Hep C, hire heroin addicts with Hep
C and you get a larger testbed of lab mice to work with]
Ashton Daigle, 27, struck a plea deal that will result in a minimum sentence of
54 months in prison when he is sentenced on Oct. 26.
Daigle said he sprayed the drug into his nose.
Aflatoxin
- Hepatitis B - Liver Cancer - Genetic Warfare - Eugenics
Have you ever heard of Typhoid Mary? Well, Here is a Hepatitis C
- Typhoid Mary:
infectious silent chronic HCV carriers: How many were there?
Note that this woman had no reason to have HCV, yet had it. The HCV infection
she had put off NO anti-bodies that could be used to screen her blood. She
donates blood for years and the recipents come down with HCV.
http://www.ncbi.nlm.nih.gov/pubmed/10919211
Discovery of a chronic HVC infection without seroconversion in a blood donor
in France during 28 months
ETS Bretagne, Rennes, France.
The HCV-RNA screening technique developed by the French Fractionation and
Biotechnology Laboratory singled out in March 1998 a case of positive HCV-RNA
viremia in a blood donor without any anti-HCV antibody.
That donor was a 46-year-old woman who had made 54 donations of blood
products from 1988 to 1997. She had no history of blood transfusion, no history
of hepatitis and no life-style risk factor.
Clinical examination was normal. Liver tests (serum alanine amino transferases,
gamma glutamyl transpeptidase , alkaline phosphatase, bilirubin , prothrombin
and albumin) were normal. Total blood count was normal. Lymphocyte count was
normal as well as in vitro functional analysis of lymphocytes (stimulation with
different antigens).
All screening HCV Elisa tests and immunoblot System available on the French
market were unable to detect anti-HCV antibodies. Quantification of serum
HCV-RNA (Amplicor Monitor Roche) showed 294,000 copies/mL and HCV genotype 1b
determination was performed using Innolipa assay.
Further examination of the HCV genotype by direct sequencing of the PCR
product showed a classical 1b genotype sequence. The hemovigilance inquiry
identified 25 labile products distributed since 1988.
Analyzing the records of the recipients that have so far been traced and
identified revealed three periods: 1997 to 1995: three recipients were found
to be positive for anti-HCV antibodies; two are now cured of hepatitis C. In one
recipient, direct sequencing after specific PCR of the hypervariable region
coding for the envelope domain showed 100% homology with the donor;
1993 to 1990: four recipients were identified and traced without contamination;
in 1988: three of four blood product recipients were anti-HCV negative without
HCV-RNA viremia. The forth carried anti-HCV antibodies and genotype 1b HCV-RNA
but had a history of multiple surgery. Alter et al. [4] and Bush et al. [5] have
previously suggested the possibility of a chronic, immunologically silent
state of infection.
The case described herein, is the first evidence for this hypothesis.
Indeed, the donor has not yet seroconverted 28 months after viremia was
discovered. This blood donor was identified by HCV-RNA screening of plasma
products. The identification of the same sequence in a recipient of blood from
this donor clearly establishes the transmission of the virus by transfusion.
The prevalence of such cases of infectious silent chronic HCV carriers has to
be determined and the mechanisms responsible for the absence of antibody
production need to be clarified.
Even the CDC admits there are people getting this for no apparent reason:
http://www.cdc.gov/mmWR/PDF/rr/rr4719.pdf
Recommendations for Prevention and Control of Hepatitis C Virus (HCV)
Infection and HCV-Related Chronic Disease
...
Persons with No Recognized Source for Their Infection.
...
Thus, a potential risk factor can be identified for approximately 90% of
persons with HCV infection.
In the remaining 10%, no recognized source of infection can be identified,
although most persons in this category are associated with low socioeconomic
level. Although low socioeconomic level has been associated with several
infectious diseases and might be a surrogate for high-risk exposures, its
nonspecific nature makes targeting prevention measures difficult.
And G whiz Rockefeller U. and the Gates Foundation is heavy
into HCV research and creating NEW strains of HCV:
http://newswire.rockefeller.edu/index.php?page=engine&id=491
Posted: March 27, 2006
Researchers show laboratory hepatitis C strain is also infectious in animal
models
An important step in developing a treatment for viral diseases is for
scientists to culture live viruses from infected patients, but the
hepatitis C virus (HCV), a major cause of chronic and sometimes fatal liver
disease, has proven to be particularly wily.
For many years scientists have struggled with an inability to efficiently
culture HCV in the laboratory.
Now, researchers at Rockefeller University have overcome several
obstacles and successfully shown that a strain of HCV they created in the
laboratory, which can efficiently be cultured in vitro, is also infectious in
animals. The findings, reported in the March 7 issue of the Proceedings of
the National Academy of Sciences, will enable scientists to study the life cycle
of HCV at the molecular level and develop better treatments for this disease.
The researchers, led by Brett Lindenbach at Rockefeller and Philip Meuleman at
Ghent University in Belgium, used a cell-culture version of HCV, developed by
Lindenbach and colleagues at Rockefeller, called HCVcc. HCVcc, which was
the first infectious cell-culture version of hepatitis C, was used to infect two
chimpanzees as well as mice bearing human liver grafts. The researchers found
that in both the chimpanzees and the mice, hepatitis C infection lasted for as
long as 15 weeks. Also, the infections raised in the mice could be passed to
other mice. Samples of the test tube-cultured strain could be recovered from
infected animals and was easily recultured in vitro, unlike most other
strains of HCV isolated from infected animals or people.
“The ability to study a genetically defined virus in the test tube and in
living animals allows us to completely dissect the HCV life cycle,” says
senior author Charles Rice, Maurice R. and Corinne P. Greenberg Professor
and head of the Laboratory of Virology and Infectious Disease at Rockefeller.
...
http://www.rockefeller.edu/research/abstract.php?id=143
Heads of Laboratories Charles M. Rice, Ph.D.
Maurice R. and Corinne P. Greenberg Professor
Laboratory of Virology and Infectious Disease
E-mail: ricec@rockefeller.edu
...
A major roadblock in HCV antiviral development and vaccine research is
establishing a small animal model where HCV replication, immunogenicity and
pathogenesis can be studied. The Rice lab is working with an international
consortium, funded by a Gates Foundation Grand Challenges grant, on methods to
implant human liver cells and immune cells in mice. Success in creating such
an animal model for HCV will have broad implications for developing vaccines for
HIV, malaria and other uniquely human pathogens
...
So we have Bio-weapons diseases
developed by the military and distributed by the blood banks, Bayer Corporation,
Baxter Corporation and American Red Cross etc...
They give the early 1948 date for HCV but it sounds like "backdating"
the disease to me.
Must read:
http://www.hcvets.com/data/transmission_methods/vaccine_contamination.htm
Hepatitis C Origin
http://www.hcvets.com/data/transmission_methods/published_articles/studies.htm#Hepatitis
C Origin
Points to Possible Military Link Copyright 1999 by Forward Times- DOCUMENTS
RAISE QUESTIONS ABOUT VIETNAM ERA EXPERIMENTS ED WENDT-Documents obtained by
Forward Times under the Freedom of Information Act, for an investigation of
the hepatitis C epidemic, reveal that U.S. servicemen were used to test
experimental vaccines while they were in Basic Combat Training during the
Vietnam Era”
“ blood samples of American servicemen taken in 1948 were recently reviewed
during a study. Those samples detected the hepatitis C virus.”
http://nationalhepatitiscinstitute.org/Data/Transmission/ISGContamination.htm
Baxter Agrees to Settle Hepatitis C Claims Related to Use of Immune Globulin
WESTPORT, Dec 22 2000 (Reuters Health) - Baxter Healthcare has agreed
to the terms of a proposed class action settlement brought by individuals who
contracted or were exposed to hepatitis C virus through use of Baxter's immune
globulin therapy, Gammagard, between January 1, 1993 and February 24, 1994.
Financial terms of the settlement were not disclosed by Baxter or the
plaintiffs' class counsel. However, the Deerfield, Illinois medical
products firm said that members of the class would receive financial
compensation.
Baxter voluntarily withdrew the immune-boosting product from the market in
February 1994 after receiving reports from more than 200 patients who
claimed that they were infected with hepatitis C virus after using Gammagard.
In the November 1996 issue of the Journal of the American Medical Association,
Dr. Joseph S. Bresee of the US Centers for Disease Control and Prevention and
colleagues reported on a study of nearly 300 patients who received immune
globulin between March 1993 and February 1994. As reported by Reuters
Health, the researchers found that 11% of the patients who received Gammagard
had contracted hepatitis C virus compared with none who received other products
exclusively.
In may 1994 Baxter launched Gammagard S/D, whose manufacture includes an
additional processing step that inactivates viruses such as hepatitis C.
There have been no reports of hepatitis C virus associated with Gammagard S/D,
according to the company.
According to terms of the proposed settlement, patients who received Gammagard
during the class action period could receive free test to determine whether they
have contracted hepatitis C virus. Those who are infected with the virus
are eligible to receive payments based on progression of the illness.
Those who did not contract the virus are also eligible for payment, according to
Baxter.
John Evans of Specter, Specter, Evans & Manogue, the Pittsburgh,
Pennsylvania-based lead counsel for the plaintiff class, said that the
settlement "...was designed with individual patients' needs in mind,
providing financial relief based on specific medical symptoms of hepatitis C
they may exhibit today or in the future."
Baxter noted that the estimated cost of the settlement will be covered by
previously established financial reserves. The settlement must receive
approval from the judge overseeing the class action
Immune Globulin IVIG
Immune Globulin intravenous IVIG is a protein found in the plasma component of
blood. Plasma is collected and pooled by domestic fractionators such as
Bayer Corporation, Baxter Corporation and American Red Cross. Igiv is
prepared as a sterile solution, contains no preservatives and is treated to
prevent transmitting viruses. The U.S. Food and Drug Administration
regulates its preparation, distribution and use.
Immune globulin is used to treat primary immunodeficiency's. It is especially
useful when high levels or elevation of circulating antibodies are desired.
Immune globulin comes in sterile solution or lyophilized powder and is
administered intravenously.
http://www.sciencenews.org/view/generic/id/43337/title/New_weapon_fights_hepatitis_C
New weapon fights hepatitis C
Experimental drug clears hurdle on its way to joining standard drug
combinations
By Nathan Seppa
May 23rd, 2009; Vol.175 #11 (p. 12)
Ten years ago, John McHutchison never used the word “cure” when
discussing hepatitis C with his patients. But the results seen from drugs
cleared for use since then — and particularly a new drug now in the final
stages of testing — are changing that, says the gastroenterologist from Duke
University in Durham, N.C.
“As far as these patients are concerned, they’re pretty much cured,”
McHutchison says. “We don’t need to see them anymore.”
The new drug, called telaprevir, works with a standard hepatitis C drug
combination to clear the virus from patients’ blood substantially better than
the standard treatment alone, according to a study coauthored by McHutchison and
another study, both in the April 30 New England Journal of Medicine. The new
findings, in people getting their first course of drugs for the disease caused
by the virus, also indicate that typically lengthy hepatitis C treatment could
be halved with telaprevir’s addition.
“Telaprevir appears to be a material advance in the therapy of hepatitis C,
beginning a new era of treatment,” says physician Jay Hoofnagle of the
National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Md.,
writing in an editorial in the same NEJM issue. Unlike existing hepatitis
drugs, telaprevir is a protease inhibitor.
A third study finds that about half of people who hadn’t responded to initial
treatment for hepatitis C or had relapsed cleared the virus after getting the
combination including telaprevir. Those data were presented April 25 in
Copenhagen at a meeting of the European Association for the Study of the Liver.
In general, patients are considered cured if they don’t have detectable
hepatitis C virus for six months after drug treatment. More than 99 percent of
such patients continue to stay free of the virus for the next five years, says
Jean-Michel Pawlotsky, a hepatologist at the Henri Mondor Hospital in Créteil,
France, and coauthor of the other study in NEJM.
The researchers agree that the drug can cure many of those patients who have
received treatment but were still fighting a losing battle with hepatitis C.
“We had to tell them we had nothing to offer,” Pawlotsky says. “Now there
might be something to offer.”
McHutchison and his colleagues randomly assigned 250 hepatitis C patients to get
the standard drugs ribavirin and peginterferon alfa-2a, with or without
telaprevir. The team found that 61 to 67 percent of those getting telaprevir
were cured, compared with 41 percent of those not getting it.
Pawlotsky and his colleagues looked at 334 patients in Europe. The cure rates
ranged from 60 to 69 percent with telaprevir compared with 46 percent with
ribavirin and peginterferon alfa-2a alone, Pawlotsky says.
Both studies in NEJM found that taking telaprevir for three months and the
standard drugs for five and a half months worked as well as taking the standard
drugs for the usual 11-month course.
In the study reported at the Copenhagen meeting, 453 patients who had failed to
respond to earlier treatment or had relapsed afterward were similarly assigned
to get telaprevir or not as part of a combination. Hepatologist Michael Manns of
the Hannover Medical School in Germany and his colleagues reported that slightly
more than half of those getting telaprevir were cured, compared with only 14
percent of those getting just standard drugs.
The studies were funded by Vertex Pharmaceuticals of Cambridge, Mass., which
makes telaprevir. Schering-Plough also makes a protease inhibitor, called
boceprevir, which tested well against first-time–treated hepatitis C patients,
according to other researchers presenting data at the Copenhagen meeting.
About 3.2 million people in the United States have hepatitis C. It infects about
180 million people worldwide. Hepatitis C can cause fatigue, fever, jaundice and
abdominal pain. Patients who fail to improve during treatment or who relapse
afterward risk developing cirrhosis of the liver and liver cancer. The virus
comes in four varieties. In these studies, all patients had genotype 1, the most
common and difficult-to-treat kind in Europe and North America.
Both telaprevir and boceprevir are currently in large-scale trials now.
McHutchison says he expects both to get approved, possibly as early as 2011.
Hemopurifier - Another treatment is to filter the blood... Baxter has one
of these too....
So these blood companies put HCV into the blood and now they are going to filter
it out. Great.
Oh bio-filter's = Battelle
http://www.accessmylibrary.com/coms2/summary_0286-37480300_ITM
AETHLON HEMOPURIFIER ADJUNCT THERAPY FOR HEPATITIS-C.
Publication Date: 01-MAY-09
COPYRIGHT 2009 Worldwide Videotex
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), San Diego, has announced
clinical data that supports the advancement of the Aethlon Hemopurifier(R) as an
adjunct therapy to increase Hepatitis-C (HCV) cure rates. The Hemopurifier(R)
is a first-in-class medical device that assists the immune response in combating
infectious disease through real-time therapeutic filtration of infectious
viruses and immunosuppressive proteins. In HCV care, the device inhibits
viral replication through selective elimination of HCV in circulation and
assists to preserve immune cells by removing toxic proteins shed from the
surface of HCV.
Aethlon disclosed that data resulting from over 20 HCV treatments indicates
an average viral load reduction of 41% during each four-hour Hemopurifier(R)
treatment.
In the studies, average pre-treatment viral load of 22,868,000 HCV virus
copies/ml blood (cpm) was reduced on average by 9,300,000 cpm during the course
of each treatment. Based on this data, Aethlon predicts that short-term continuous
Hemopurifier(R) treatment can reduce viral load to low to undetectable levels,
thus improving the likelihood that HCV patients achieve a sustained virological
response (SVR) from the current interferon-ribavirin standard of care and other
candidate therapies.
HCV infection is considered cured when SVR extends beyond six months. At
present, less than 50% of HCV patients respond to interferon-ribavirin therapy.
Additionally, there is a direct correlation between low viral load at onset of
interferon-ribavirin therapy and increased cure rates. Based on data analyzed
from each four-hour Hemopurifier(R) treatment, Aethlon projects that a
patient with a high viral load of 7 million iu/ml would be reduced to
undetectable HCV levels after approximately three days of continuous
Hemopurifier(R) treatment.
This corresponds to a 4.06 log reduction or an 11,000-fold decrease in viral
load. An HCV patient with a moderate viral load of 2 million iu/ml would be
projected to reach undetectable levels in approximately 2.5 days of continuous
treatment. All of the studies were conducted in highly health compromised HCV
infected patients who suffer from end-stage renal disease (ESRD) requiring
regular kidney dialysis treatment. In these treatment studies, the
Hemopurifier(R) inhibited the progression of HCV infection in ESRD patients when
included during dialysis treatment administered thrice weekly for four-hours. The
studies were conducted at the Fortis Hospital in Delhi, India.
About Hepatitis-C Virus
HCV is a leading cause of chronic liver disease and liver transplants. The World
Health Organization (WHO) estimates that nearly 180 million people worldwide, or
approximately 3% of the world's population, are infected with HCV.
130 million of these individuals are chronic HCV carriers who are at increased
risk of developing liver cirrhosis or liver cancer, approximately 15 million of
whom are in the United States, Europe and Japan.
The CDC has reported that almost four million people in the United States have
been infected with HCV, of whom 2.7 million were chronically infected.
Approximately 2.6%, or 71,000, of these HCV patients are treated each year.
Although chronic HCV infection varies greatly in its course and outcomes, 70%
of chronically infected patients develop some form of chronic liver disease,
including, in some cases, cirrhosis or liver cancer.
In the United States, the current standard of care for the treatment of HCV
is a combination of pegylated interferon and a nucleoside analog named ribavirin.
According to WHO, treatment with interferon in combination with ribavirin is
effective in 30% to 50% of patients, while interferon alone is effective in
approximately 10% to 20% of patients.
In HCV genotypes 1a and 1b, which account for over 70% of HCV infections in
the US, less than 50% of these patients respond to standard therapy consisting
of pegylated interferon plus ribavirin.
In addition, these therapies have serious side effects that include fatigue,
bone marrow suppression, anemia and neuropsychiatric effects. As a result of
the limited benefits and serious side effects of existing therapies, significant
value is placed on promising antiviral strategies to fight HCV. The Aethlon
Hemopurifier(R) is positioned to improve the benefit of the current interferon-ribavirin
standard of care, as well as other candidate HCV drug therapies demonstrating
promise in clinical studies.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic filtration devices to improve
the health of individuals afflicted with infectious disease and cancer.
Aethlon's lead product, the Hemopurifier(R), is a first-in-class artificial
adjunct to the immune system proven to capture infectious viruses and
immunosuppressive particles from the human circulatory system.
The device targets to inhibit disease progression of Hepatitis-C Virus (HCV)
and Human Immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment
countermeasure against bioterror and emerging pandemic threats.
The Hemopurifier(R) also holds promise in cancer care, as research studies
verify the Hemopurifier(R) effectively captures immunosuppressive exosomes that
are secreted by tumors to kill-off immune cells. At present, over sixty-five
(65) Hemopurifier(R) treatments (representing approximately 260 hours of
treatment time) have been conducted in multi-site studies at the Apollo
Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The
studies enrolled end-stage renal disease (ESRD) patients infected with either
HCV or HIV. In addition to establishing treatment safety, robust viral load
reductions have been reported in both HCV and HIV infected individuals.
Research studies have also demonstrated the Hemopurifier(R) is effective in
capturing a broad-spectrum of viruses untreatable with drug therapy, including
several of world's deadliest bioterror and pandemic threats.
These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF),
Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), the
reconstructed 1918 influenza virus (r1918), West Nile virus (WNV), and Vaccinia
and Monkeypox (MPV), which both serve as models for human smallpox infection.
The studies were conducted with the assistance of researchers representing: The
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID); The
Centers for Disease Control and Prevention (CDC); The National Institute
of Virology (NIV); The Battelle Biomedical Research Center (BBRC); and
The Southwest Foundation for Biomedical Research (SFBR).
Beyond therapeutic market opportunities, Aethlon is leveraging principles
underlying the Hemopurifier(R) technology platform to establish a pipeline of
clinical and research diagnostic products and services.
For more information, visit http://www.aethlonmedical.com/
or call 858/459-7800, ext. 303.
Hep C is a silent killer epedemic.... you did read the TyphoidMary Hep-C-Mary
post above?
http://www.prn.org/index.php/coinfections/article/acute_hepatitis_c_infection_433
Therapeutic Implications of Acute Hepatitis C Infection
Elmar Jaeckel, MD
Department of Cancer Immunology and AIDS
Dana-Farber Cancer Institute
Boston, Massachusetts
The hepatitis C virus's greatest weapon might very well be its silence. It is
an infection that is initially asymptomatic and often goes unrecognized,
anywhere from several years to more than two decades after the infection has
established itself in the liver. Because of this, countless individuals
in this country and elsewhere are not aware that they are, in fact, chronically
infected with the virus.
This is also true during the acute stage of infection. While symptoms such as
fatigue, lethargy, myalgia, low-grade fever, nausea and vomiting do occur in
patients with acute HCV infection, they are virtually indistinguishable from
more common and benign viral infections and, as a result, usually go unchecked.
Even one of HCV's hallmark features-jaundice-develops in fewer than half of
all individuals during acute infection, even though HCV-RNA and liver enzyme
levels are usually at their highest.
....
[author goes on to say how great interferon is....]
Eugenics Business Model:
Exactly - they hit up to
2-3% of the world population with Global-Genocide penetration and then start
bringing out the "cures" which they make more money on. Rinse and
repeat.
It's so sick... and added bonus, the "cure" makes you suicidal...
Kidney Dialysis
Machines spreading HCV (in China):
http://www.upi.com/Health_News/2010/01/06/Hospital-reports-hepatitis-C-outbreak/UPI-75841262802517/
Hospital reports hepatitis C outbreak
Published: Jan. 6, 2010 at 1:28 PM
ANQING CITY, China, Jan. 6 (UPI) -- Fifteen kidney dialysis patients were
infected with hepatitis C at a hospital in China's Anhui Province,
authorities said.
The patients were infected at Yicheng Hospital, said health officials, who
opened an investigation last month after several patients with renal issues were
diagnosed with the disease.
Thirty-nine of 77 dialysis patients treated at the hospital were found to
have hepatitis C, but only 15 cases could be linked to the hospital's dialysis
clinic, Xinhua, China's state-run news agency, reported Wednesday.
"There's a chance that some of the patients may have had the disease before
taking the dialysis treatment," an unidentified health official told Xinhua.
Patients confirmed to have contracted hepatitis at the hospital would receive
free treatment, the spokesman said.
In America:
http://medical-malpractice.lawyers.com/blogs/archives/928-Hepatitis-C-Outbreak-at-Atlantic-City-Hospital.html
Hepatitis C Outbreak at Atlantic City Hospital
Tuesday, May 5, 2009 by Joseph L. Messa
Officials at have reported 15 cases of hepatitis C at AtlantiCare Regional
Medical Center in Atlantic City, New Jersey. Administrators from the
AtlantiCare Regional Medical Center’s City Campus contacted the state this
month after discovering five recent cases of hepatitis C during an annual
federally mandated hepatitis C testing of dialysis patients.
Testing took place in April as well as early this month. Five patients
became positive for hepatitis C since they began undergoing treatment at
AtlantiCare. Reports state that the 15 patients contracted the serious and
sometimes deadly liver disease starting in 2005.
According to New Jersey health officials, the state saw over 100 acute and
7,000 chronic hepatitis C cases in 2007, adding that the Center’s dialysis
unit treats between 70 to 80 kidney patients monthly, with patients visiting the
center three times a week for dialysis. Kidney dialysis involves the patient’s
blood being pumped into a dialysis machine, where it is filtered and returned to
the patient’s body. Dialysis machines at the center are inspected once
every two years. The hospital maintains it follows strict guidelines that
include disinfection and cleaning of the equipment.
The 15 infected patients were part of a group of 245 patients. The
dialysis center has a lower-than-average patient survival rate when compared to
the state. The origin of the virus is still unknown. Patricia
Diamond, Atlantic County Health Officer, said finding the source of the virus
might not be easy. “Any investigation of a communicable disease is not
black and white. They are complicated. All of the information has to be
carefully reviewed before anything is determined.” Improper maintenance
or use of dialysis machines is medical malpractice.
The hospital, the state, and health officials are diligently working to
determine the cause and origin of the virus.
HVC spreading in Hospitals:
http://www.attorneyatlaw.com/2010/01/judge-rejects-plea-deal-for-hepatitis-c-hospital-tech/
http://www.attorneyatlaw.com/2009/09/former-surgical-tech-admits-infecting-patients-with-hepatitis-c/
Former Surgical Tech Admits Infecting Patients With Hepatitis C
A former Colorado surgical technician has pleaded guilty to federal charges she
stole pain drugs then shared the dirty needles with patients, exposing thousands
of people to a risk of Hepatitis C.
Kristen D. Parker, who also worked at hospitals in New York and Texas,
pleaded guilty to charges of tampering with a consumer product and obtaining a
controlled substance by deceit. She now faces a 20-year prison sentence when she
is formally sentenced, according to a New York Times report.
Parker fed her addiction to pain-killing drugs by taking medications set aside
for surgical patients, injecting the drugs into herself, then filling the
syringes with saline solution and returning them to surgical trays for later use
on patients.
States Investigate Possible Infections
At least 27 patients at Rose Medical Center in Denver and Audubon Surgery
Center in Colorado Springs, where Parker worked from October 21, 2008 until July
6, 2009, have tested positive for the serious blood disorder that can
permanently affect liver functioning, officials said.
Officials also warned thousands of other patients at Northern Westchester
Hospital Mount Kisco, New York and Christus St. John Hospital near Houston,
where Parker worked before moving to Colorado. It is unclear how many
patients may have been exposed to dirty needles at those facilities, but
officials sent warning letters to more than 6,000 people who underwent surgical
procedures during Parker’s stints there.
Parker was arrested over the summer, indicted on more than 40 federal charges,
and faced a possible life prison term if convicted. However, she agreed to plead
guilty and in exchange for that cooperation now faces a maximum term of 20
years, officials said.
http://www.attorneyatlaw.com/2009/07/hospital-worker-arrested-accused-of-exposing-thousands-to-hepatitis-c/
Hospital Worker Arrested, Accused of Exposing Thousands to Hepatitis C
As many as 6,000 patients who underwent surgery at a Denver-area hospital
over a six-month period are being advised to have a blood test to determine
whether they were exposed to hepatitis C by a hospital worker.
Kristen Diane Parker, a 26-year-old surgical scrub nurse at Rose
Medical Center, has been accused of using syringes filled with painkillers meant
for patients on herself, then refilling the syringes with saline solution.
Parker allegedly was addicted to painkillers and was feeding her addiction by
stealing the drugs intended for use in surgical patients. By reusing the needles
she used to inject herself on patients, officials say Parker exposed
thousands of patients to hepatitis C.